scorecardresearchGlenmark Pharmaceuticals Share Price Live NSE, BSE, Today - Glenmark Pharmaceuticals Stock Price

Glenmark Pharmaceuticals

BSE: 532296 | NSE: GLENMARK | ISIN: INE935A01035 | SECTOR: Biotechnology & Drugs

385.00 -4.25 (-1.09%)

03 Feb 2023, 09:59 (IST)
  • Open

    389.25
  • High

    390.85
  • Low

    381.65
  • Prev Close

    389.25
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    -
  • Volume

    24.88K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
  • Div.Yield

    -
  • Bid

    385.80
  • Ask

    -

Company Description

  • Biotechnology & Drugs
  • BSE

    532296
  • NSE

    GLENMARK
  • ISIN

    INE935A01035

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is primarily engaged in the business of developing, manufacturing and marketing of pharmaceutical products. It focuses on manufacturing products across therapeutic areas of respiratory, dermatology and oncology. It is involved in development of new chemical entities (NCEs) and new biological entities (NBEs). Its business segments include India, North America, Europe and Rest of the world. It is focused on developing and marketing branded and generic formulations. Its products include FabiFlu, Ryaltris and Remo (Remogliflozin etabonate). Its FabiFlu is an antiviral medication to treat mild to moderate COVID-19. Its Ryaltris is a fixed-dose combination nasal spray of an antihistamine (olopatadine hydrochloride 665 microgram) and a steroid that treats symptoms associated with seasonal, as well as perennial allergic rhinitis. Its Remo is a sodium-glucose transport-2 (SGLT2) inhibitor for the type 2 diabetes.

Company Officers

  • Glenn Saldanha

    Executive Chairman of the Board, Chief Executive Officer, Managing Director
  • V. S. Mani

    Global Chief Financial Officer, Executive Director
  • Harish Kuber

    Compliance Officer, Company Secretary
  • Cherylann Pinto

    Executive Director - Corporate Services